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doi:10.1016/j.jtcvs.2006.04.010bjective: At present, there is no prognostic model that is specific for prediction of
urvival after non–small cell lung cancer surgery. We aimed to develop a prognostic
odel that can be used to estimate the postoperative survival of individual patients.
ethods: A total of 766 patients underwent resection for primary non–small cell
ung cancer. Comorbid conditions were scaled according to the Charlson comor-
idity index (CCI). Cox proportional hazard analyses were used to determine risk
actors for survival. A prognostic model for survival with a preoperative and
ostoperative mode was established. Performance of the prognostic model, the CCI,
nd pathologic tumor stage were quantified by a concordance statistic to indicate
iscriminative ability.
esults: The factors associated with an impaired survival were male sex, age,
hronic obstructive pulmonary disease, congestive heart failure, any prior tumor,
oderate-to-severe renal disease (preoperative and postoperative mode), clinical
umor stage (preoperative mode), type of resection, and pathologic tumor stage
postoperative mode). The discriminative performance was poor for the CCI (c 
.55), better for pathologic tumor stage (c  0.60) and for the preoperative mode
c  0.61), and best for the postoperative mode (c  0.65). The discriminative
erformance of the postoperative mode was better than the discriminative perfor-
ance of the CCI (P  .0001), the preoperative mode (P  .0002), and pathologic
umor stage (P  .0001). The discriminative performance of the preoperative mode
as better than the discriminative performance of the CCI (P  .0001) and similar
P  .90) to a model that only included pathologic tumor stage.
onclusions: The prognostic model, particularly the postoperative mode, success-
ully estimates long-term survival of individual patients and could help clinicians in
linical decision-making and treatment tailoring.
urgical resection is generally the mainstay of curative treatment in early-stage
non–small cell lung cancer (NSCLC). Survival is mainly dependent on patho-
logic tumor stage, with a 5-year survival that ranges between 67% and 38% for
athologic tumor stage IA to IIB.1,2 However, many other factors also have an impact
n survival, such as comorbidity, age, and type of resection.3-6 Owing to the increasing
ge of the population diagnosed with NSCLC, the incidence of comorbidity and
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TSonsequently high-risk patients also increases. The most fre-
uent comorbidities in patients with NSCLC are cardiovascu-
ar disease (23%), chronic obstructive pulmonary disease
COPD) (22%), and other malignancies (15%).7
Several scoring systems based on various comorbid condi-
ions have previously been used to stratify patients according to
isk of complications and long-term survival after NSCLC
urgery.8-11 In previously published studies we8,9 found the
harlson comorbidity index (CCI) to predict postoperative
utcome more accurately than the individual comorbid condi-
ions. However, these scoring systems are developed in other
atient populations and thus may be suboptimal for application
n patients having NSCLC surgery. In addition, these models
o not include several other prognostic factors in patients
aving NSCLC surgery, such as sex, age, extent of resection,
nd tumor stage. Furthermore, these models do not estimate the
ong-term survival of individual patients after surgical resec-
ion. At present, there is no accepted prognostic model that is
pecific for NSCLC patients and one that can be used to
stimate the long-term survival of individual patients after
urgical resection of NSCLC.
In addition, to provide surgeons and patients with better
uality information on risk assessment and postoperative
urvival, we performed this retrospective study. We aimed
o identify prognostic factors for survival in NSCLC sur-
ery, to develop a prognostic model with a preoperative and
ostoperative mode to estimate survival of individual pa-
ients, and to compare the predictive accuracy of the prog-
ostic model with the predictive accuracy of the CCI and
athologic tumor stage.
ethods
atients
e retrospectively reviewed the medical records of 766 consecutive
atients who underwent resection for primary NSCLC at the Depart-
ents of Cardio-Thoracic Surgery of the Erasmus MC Rotterdam
433 patients) and the Leiden University Medical Center (333 pa-
ients), from January 1, 1989, through December 31, 2001. Patients
ere followed up with regular visits to the outpatient clinic. Civil
dministrations were consulted to assess late mortality. Follow-up
as completed through August 2004. Survival time was defined as
he difference between the date of surgery and the date of last
Abbreviations and Acronyms
CCI  Charlson comorbidity index
CI  confidence interval
COPD  chronic obstructive pulmonary disease
FEV1  forced expiratory volume in 1 second
GOLD  Global Initiative for Chronic Obstructive
Lung Disease
NSCLC non–small cell lung cancerollow-up. Hospital mortality was defined as death occurring within l
92 The Journal of Thoracic and Cardiovascular Surgery ● Septe0 days of surgery or any death later during the same postoperative
ospital stay.
In all patients, preoperative diagnostic workup included a com-
lete medical history, physical examination, plain chest radiogra-
hy, electrocardiography, routine laboratory tests, lung function
ests, and computed tomography of the chest and upper abdomen.
dditional staging procedures, namely, mediastinoscopy and liver,
one, and brain scans were selectively performed to aid in treat-
ent planning according to best clinical practice at the time of
resentation. In retrospect, each patient was assessed for preoper-
tive CCI.8,9 The index can be divided into four comorbidity
rades: 0, 1 to 2, 3 to 4, and 5 or more.
COPD as a comorbid condition is defined according to the
OLD criteria (Global Initiative for Chronic Obstructive Lung
isease) as a postbronchodilator forced expiratory volume in 1
econd (FEV1)/forced vital capacity ratio less than 70%.12
Histologic typing occurred according to the World Health Orga-
ization Histologic Typing of Lung Tumours.13 Clinical and patho-
ABLE 1. Patient characteristics
Characteristic No. of patients (%)
Sex
Male 600 (78)
Female 166 (22)
Age (y)
70 534 (70)
70 232 (30)
Mean  SD 64.5 9.2
Median follow-up (y) SD 3.5 0.3
Smoking habits
Nonsmoker 88 (11)
Current or former smoker 678(89)
COPD*
No 245 (35)
Yes 464 (65)
FEV1%†
70 186 (26)
70 534 (74)
CCI
0 228 (30)
1-2 382 (50)
3-4 136 (18)
5 20 (3)
Clinical stage
IA 341 (45)
IB 291 (38)
IIA 17 (2)
IIB 57 (7)
IIIA 37 (5)
IIIB 17 (2)
IV 5 (1)
CI, Charlson comorbidity index; COPD, chronic obstructive pulmonary
isease; FEV1%, forced expiratory volume in 1 second expressed as a
ercent of predicted; SD, standard deviation. *COPD was unknown in 57
atients. †FEV1% was unknown in 46 patients.ogic tumor staging of the patients occurred according to the interna-
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TSional TNM classification for lung cancer.1 Staging was based on
athologic assessment of the primary tumor, and lymph node assess-
ent was carried out with preoperative mediastinoscopy (clinical–
athologic staging) or surgical sampling of bronchopulmonary, hilar,
nd mediastinal lymph nodes (pathologic staging).
The following risk factors for survival were evaluated: sex, age,
ype of resection, histologic cell type, smoking, COPD (unknown
n 57 patients), FEV1% (unknown in 46 patients), clinical tumor
tage, pathologic tumor stage, neoadjuvant therapy, adjuvant ther-
py, and each common condition of the CCI.
tatistical Analysis and Development of the
rognostic Model
iscrete variables are displayed as proportions, and continuous vari-
bles are displayed as means  standard deviations unless specified
therwise. We used the Cox proportional hazard analysis to determine
isk factors for survival, where effects were expressed as relative risks
ith 95% confidence intervals (CI). Multivariate analysis was per-
ormed with stepwise backward elimination of variables, starting with
model in which each variable with a P value of less than .20 in the
nivariate analysis was entered. Because COPD, FEV1%, and chronic
ulmonary disease were correlated to each other, we entered only the
ost significant factor (COPD) in the multivariate analysis. In the
ultivariate analysis the estimated mean value of COPD was imputed
or the 57 missing values.
Preoperative and a postoperative modes of the prognostic
ABLE 2. Charlson comorbidity index and prevalence
f comorbid conditions among 766 patients operated on
or NSCLC
core Condition No. of patients (%)
1 Coronary artery disease* 141 (18.4)
Congestive heart failure 145 (18.9)
Chronic pulmonary disease 226 (29.5)
Peptic ulcer disease 46 (6.0)
Peripheral vascular disease 86 (11.2)
Mild liver disease 1 (0.1)
Cerebrovascular disease 50 (6.5)
Connective tissue disease 7 (0.9)
Diabetes 40 (5.2)
Dementia 2 (0.3)
2 Hemiplegia 2 (0.3)
Moderate to severe renal disease 20 (2.6)
Diabetes with end-organ damage 2 (0.3)
Any prior tumor (within 5 years of
diagnosis)†
140 (18.3)
Leukemia 5 (0.7)
Lymphoma 10 (1.3)
3 Moderate to severe liver disease 3 (0.4)
6 Metastatic solid tumor 2 (0.3)
AIDS (not only HIV positive) 0 (0)
IDS, Acquired immunodeficiency syndrome; HIV, human immunidefi-
iency virus; NSCLC, non-small cell lung carcinoma. *Including myocardial
nfarction, coronary artery bypass graft, percutaneous transluminal coro-
ary angioplasty, and angina pectoris. †Except basal cell skin carcinoma.odel for survival were established. This model considered sex I
The Journal of Thoracicnd age and included those factors that were available preopera-
ively or postoperatively that were associated with an impaired
urvival in the multivariate analysis. Factors that were less impor-
ant but almost significant, such as COPD, congestive heart failure,
nd left-sided pneumonectomy, were retained in the model be-
ause of their documented relevance in the literature.5,14-16 The
erformance of the prognostic model, the CCI, and pathologic
umor stage were quantified by a concordance statistic (c statistic),
hich is similar to the area under the receiver operating charac-
eristic curve for binary data.17 A c statistic of 0.5 indicates that the
odel has no discriminative ability, and a c statistic of 1 indicates
hat the model perfectly distinguishes between those who die early
nd those who die later.
Bootstrapping techniques were used for internal validation of
he c statistic of the models.14,18 Bootstrap samples were drawn
ith replacement and with the same size as the original sample.
egression models were created in each bootstrap sample and
ested on the original sample. This procedure was repeated 200
imes to obtain stable estimates of the optimism of the model, that
s, how much the model performance was expected to decrease
hen applied in future patients.19
Bootstrap resampling was also used to test differences in per-
ormance between alternative models. The mean difference and
tandard error was estimated from 2000 bootstraps.
For practical application, we developed an Excel spreadsheet in
hich preoperative and postoperative characteristics can be entered
nd the predicted survival with 95% CI is automatically calculated.
his Excel spreadsheet for easy access and use by clinicians is
vailable on the Internet (http://www.cardiothoracicresearch.nl). Sta-
istical calculations were performed with SPSS (version 12.0; SPSS
ABLE 3. Operative characteristics
haracteristic No. of patients (%)
ype of resection
Wedge resection 17 (2)
Lobectomy 470 (61)
Bilobectomy 73 (10)
Pneumonectomy 206 (27)
Left-sided 105 (14)
Right-sided 101 (13)
istology
Squamous cell carcinoma 386 (50)
Adenocarcinoma 246 (32)
Large cell carcinoma 82 (11)
Bronchoalveolar cell carcinoma 52 (7)
athologic stage
0 1 (0.1)
IA 244 (32)
IB 251 (33)
IIA 35 (5)
IIB 110 (14)
IIIA 72 (9)
IIIB 39 (5)
IV 13 (2)nc, Chicago, Ill) and S-plus (version 6.0; Insightful Corp, Seattle, Wash).
and Cardiovascular Surgery ● Volume 132, Number 3 493
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G
TSesults
f the 766 patients enrolled in this analysis, 600 (78%) were
en and 166 (22%) were women. Median follow-up time
as 3.5  0.3 years. The mean age at operation was 64.5
.2 years (range, 37-84 years). The patients’ preoperative
haracteristics are outlined in Tables 1 and 2. The types of
ABLE 4. Univariate and multivariate Cox proportional haz
ariable No. of patients RR
ale sex 600 1.3
ge 766 1.02
OPD* 464 1.2
EV1%  70 186 1.2
ype of resection
Wedge resection 17 2.1
Bilobectomy 73 1.4
Left-sided pneumonectomy 105 1.5
Right-sided pneumonectomy 101 1.7
CI
Score 1-2 382 1.1
Score  3 156 1.6
oronary artery disease† 141 1.1
hronic pulmonary disease 226 1.2
ongestive heart failure 145 1.2
oderate to severe renal disease 20 1.7
ny prior tumor‡ 140 1.2
eptic ulcer disease 46 1.0
eripheral vascular disease 86 1.0
erbrovascular disease 50 1.1
iabetes 40 1.0
eukemia 5 2.1
ymphoma 10 3.3
linical stage
IB 291 1.4
IIA 17 1.9
IIB 57 1.9
IIIA 37 1.7
IIIB 17 1.9
IV 5 10.2
athologic stage
IB 251 1.4
IIA 35 1.3
IIB 110 2.2
IIIA 72 2.6
IIIB 39 2.6
IV 13 9.0
djuvant radiotherapy 107 1.4
eoadjuvant chemotherapy 34 1.1
quamous cell carcinoma 386 1.1
CI, Charlson comorbidity index; CI, confidence interval; COPD, chronic
xpressed as a percent of predicted; RR, relative risk. *COPD was unknow
ercutaneous transluminal coronary angioplasty, and angina pectoris. ‡Wrocedures performed consisted of a wedge resection (17; w
94 The Journal of Thoracic and Cardiovascular Surgery ● Septe%), a lobectomy (470; 61%), a bilobectomy (73; 10%), a
eft-sided pneumonectomy (105; 14%), and a right-sided
neumonectomy (101; 13%). Thirty-four (4%) patients re-
eived neoadjuvant chemotherapy, no patient was treated with
eoadjuvant radiotherapy, 107 (14%) patients were treated
ith adjuvant radiotherapy, and 3 (0%) patients were treated
analysis of survival
Multivariate
ariate Preoperative Postoperative
95% CI RR 95% CI RR 95% CI
1.1-1.7 1.1 0.9-1.4 1.2 0.9-1.5
1.01-1.03 1.02 1.01-1.03 1.02 1.01-1.03
1.0-1.5 1.3 1.0-1.4 1.1 0.9-1.4
1.0-1.5
1.3-3.4 1.5 0.9-2.6
1.1-1.9 1.3 1.0-1.7
1.1-1.8 1.2 0.9-1.5
1.3-2.2 1.6 1.2-2.0
0.9-1.4
1.2-2.0
0.9-1.4
1.0-1.5
1.0-1.5 1.1 0.9-1.4 1.2 0.9-1.4
1.0-2.9 1.6 1.0-2.8 2.1 1.2-3.5
1.0-1.5 1.3 1.0-1.6 1.2 1.0-1.5
0.7-1.4
0.8-1.3
0.8-1.6
0.7-1.4
0.8-5.7
1.6-6.6
1.2-1.7 1.5 1.2-1.8
1.1-3.3 2.0 1.1-3.5
1.4-2.7 2.0 1.4-2.8
1.1-2.6 1.8 1.2-2.7
1.0-3.5 2.1 1.2-3.9
4.2-25.1 15.9 6.3-39.7
1.1-1.7 1.3 1.0-1.6
0.9-2.0 1.3 0.9-2.0
1.7-2.9 2.2 1.7-2.9
1.9-3.5 2.7 1.9-3.7
1.8-3.9 2.4 1.6-3.6
5.0-16.2 10.7 5.9-19.3
1.1-1.8 1.2 0.9-1.5
0.7-1.8
0.9-1.3
ctive pulmonary disease; FEV1%, forced expiratory volume in 1 second
7 patients. †Including myocardial infarction, coronary artery bypass graft,
5 years of diagnosis, except basal cell skin carcinoma.ard
Univ
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n in 5ith postoperative chemotherapy. Tumors were classified his-
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G
TSologically as squamous cell carcinoma (386; 50%), adenocar-
inoma (246; 32%), large cell carcinoma (82; 11%), and bron-
hoalveolar cell carcinoma (52; 7%). The patients’ operative
emographics are listed in Table 3.
Hospital mortality occurred in 34 (4.4%) patients. Of all
66 patients, 528 (69%) had died and 238 (31%) were alive
t the end of follow-up. Mean overall survival was 5.4 0.2
ears, with 77% (95% CI, 74-81) surviving at 1 year, 62%
95% CI, 58-66) at 2 years, and 40% (95% CI, 36-44) at 5
ears.
Predictors for impaired survival in the univariate analysis
ncluded male sex, age, COPD, FEV1% less than 70, type of
esection, CCI score of 3 or more, congestive heart failure,
hronic pulmonary disease, any prior tumor within 5 years
f diagnosis, moderate-to-severe renal disease, leukemia,
ymphoma, clinical tumor stage, and pathologic tumor stage
Table 4). The factors associated with an impaired survival
n the multivariate analysis were male sex, age, COPD, type
f resection, congestive heart failure, any prior tumor within
years of diagnosis, moderate-to-severe renal disease, clin-
cal tumor stage, and pathologic tumor stage (Table 4). The
eveloped Excel spreadsheet of the preoperative mode and
ostoperative mode of the model is illustrated in Figures 1 and
, respectively. In Figure 1, the clinical factors of a 64-year old
an with clinical tumor stage IB NSCLC are filled in and the
-year survival is estimated to be 33%. When this patient
ndergoes lobectomy for pathologic tumor stage IB, the 5-year
urvival is estimated to be 45% (Figure 2).
The discriminative performance (c statistic) was poor for
he CCI (c  0.55), better for pathologic tumor stage (c 
.60) and for the preoperative mode (c 0.61), and best for
he postoperative mode (c  0.65). Bootstrapping revealed
imited optimism of the model, with a decrease of the c
tatistic from 0.61 to 0.59 for the preoperative mode and
rom 0.65 to 0.63 for the postoperative mode. The discrim-
native performance of the postoperative mode was better
han the discriminative performance of the CCI (P 
0001), the preoperative mode (P  .0002), and pathologic
umor stage (P .0001). The discriminative performance of
he preoperative mode was better than the discriminative
erformance of the CCI (P  .0001) and similar (P  .90)
o a model that included only pathologic tumor stage.
iscussion
n terms of survival, NSCLC is a heterogeneous disease
ith a remarkable variation in outcome among individual
atients. During the past decades, researchers have at-
empted to identify factors that can be used to predict
utcome of patients with NSCLC. Besides tumor stage,
ther factors, such as comorbidity and extent of resection,
lso have been proven to predict survival after NSCLC
urgery.3-6 In previously published studies we8,9 found the
CI to predict postoperative outcome more accurately than T
The Journal of Thoraciche individual comorbid conditions. However, this comor-
idity index was not developed specifically for patients
aving NSCLC surgery. Therefore, only individual comor-
id conditions of the CCI that were associated with an
mpaired survival in the multivariate analysis were included
n our prognostic model. In addition, the CCI does not
nclude several other prognostic factors in NSCLC surgery
atients, such as sex, age, extent of resection, and tumor
tage, and it does not estimate the long-term survival of
ndividual patients after surgical resection.
We developed a prognostic model with a preoperative
nd postoperative mode, including tumor-related factors,
reatment-related factors, and clinical variables, for predic-
ion of survival of individual patients after NSCLC surgery.
e included prognostic factors that are all readily available
nd interpretable to the clinician. Most factors have been
ecognized as predictive in previous studies on patients
perated on for NSCLC.1,2,4,5 We note that if some appar-
ntly obvious risk factor does not appear significantly pre-
ictive (P  .05) in a multivariate model, such as conges-
ive heart failure and COPD in our study, one cannot
onclude that this is irrelevant to outcome and exclude this
articular risk factor from the prognostic model.
The postoperative mode of the prognostic model, includ-
ng pathologic tumor stage and type of resection, provided
ubstantially better discrimination than a comorbidity index
uch as the CCI (c statistic 0.65 vs 0.55, P  .0001), the
reoperative mode (c statistic 0.65 vs 0.61, P  .0002), or
nly pathologic tumor stage (c statistic 0.65 vs 0.60, P 
0001). Nevertheless, it is widely recognized that pathologic
umor stage is the most powerful predictor of long-term
urvival and the present postoperative mode of the prognos-
ic model provides only slightly better discrimination than
nly pathologic tumor stage. Moreover, owing to similar
elative risks of some tumor stages in our multivariate
nalysis, we combined these tumor stages in one subgroup.
ore patient data will be needed to improve the accuracy of
his postoperative mode of the model.
Despite the postoperative mode being the most accurate
n prediction of survival, it is important to select patients
ith a poor prognosis before surgery without knowledge of
ype of resection and pathologic tumor stage. For this pur-
ose, the preoperative mode is more appropriate, which
roved to be as accurate as only pathologic tumor stage in
rediction of survival (c statistic 0.61 vs 0.60, P  .90) and
ore accurate than the CCI (c statistic 0.61 vs 0.55, P 
0001). Therefore, the preoperative mode can be used as a
rst evaluation to estimate survival of an individual patient
nd identify patients whose prognosis is poor. Also in this
ode of the prognostic model, some tumor stages are com-
ined in one subgroup and more patient data will be nec-
ssary to improve the accuracy of this preoperative model.
he postoperative mode can either be used preoperatively
and Cardiovascular Surgery ● Volume 132, Number 3 495
Figure 1. Preoperative mode of the prognostic model: predicted survival of a 64-year old man with chronic obstructive pulmonary disease (COPD), congestive heart
failure, and clinical tumor stage IB.
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Figure 2. Postoperative mode of the prognostic model: predicted survival of a 64-year old male with chronic obstructive pulmonary disease (COPD) and congestive heart
failure who underwent lobectomy for pathologic tumor stage IB.
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G
TSo estimate survival assuming the type of resection
lanned and assuming that clinical tumor stage will not
lter after resection, or it can be used postoperatively
hen type of resection and pathologic tumor stage are
efinite. A practical version of the present prognostic model
or easy access and use by clinicians is available on the
nternet (http://www.cardiothoracicresearch.nl).
Although bootstrapping techniques were used for internal
alidation of the model, a limitation of our study is that the
rognostic model is not validated by an external test group.
his may be essential before further clinical application is
nitiated.20 In addition, this study is limited by the relatively
mall amount of clinical data that was pooled from only two
enters, in terms of both number of data and availability of
ata. For example, histopathologic cell type failed to predict
urvival in our analysis, whereas others have shown an im-
roved survival for squamous cell histology over adenocarci-
oma, large cell carcinoma, and bronchoalveolar cell carcino-
a.10,21-23 Moreover, as we stated before, we combined some
umor stages in one subgroup. We plan to further improve and
alidate the prognostic model using data from other clinics.
In conclusion, we developed a simple prognostic model
ith a preoperative and postoperative mode that may be used
or risk assessment in individual patients. The prognostic
odel successfully estimates long-term survival of individual
atients and performed well with assessments of internal va-
idity, with the postoperative mode being the most accurate.
e therefore are confident that the model will also perform
ell for future patients who face the choice between operative
reatment and other treatment modalities for NSCLC. Inclusion
f more factors with additional prognostic value could poten-
ially further improve the accuracy of the model. If further
alidated, this prognostic model could help clinicians and
atients in clinical decision-making and treatment tailoring
ased on the estimated survival after surgery.
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